Carrier cell-mediated ovarian cancer-specific cellular and immunological gene therapy by induction of CTL

能够复制的病毒已经被开发出来用于治疗癌症。然而，它们的细胞毒性作用是不够的，因为它们的感染被中和抗体的产生所抑制。为了解决这一限制，我们开发了载体细胞系统来传递具有复制能力的腺病毒。溶瘤腺病毒AdE3-IAI感染的A549载体细胞。3B杀死目标癌细胞，这种感染不受抗腺病毒抗体的抑制，并使重复感染成为可能。在通过免疫腺病毒诱导抗腺病毒CTL反应后，给感染了复制能力强的腺病毒的载体细胞注射可诱导肿瘤完全消退。腺病毒- gm - csf通过增强抗腺病毒和抗肿瘤CTL反应增强载体细胞的抗肿瘤作用。这种新的载体细胞介导的病毒转染系统可能在各种类型的癌症治疗中证明是有用的。

Replication-competent viruses have been developed to treat cancers. However, their cytotoxic effects are insufficient, because infection with them is inhibited by generation of neutralizing antibodies. To address this limitation, we developed carrier cell system to deliver a replication-competent adenovirus. A549 carrier cell infected with oncolytic adenovirus AdE3-IAI.3B killed target cancer cells and this infection was uninhibited by antiadenovirus antibody and enabled repetitive infection. After the induction of antiadenoviral CTL responses by immunization of adenovirus, administration of carrier cells infected with a replication-competent adenovirus induced complete tumor regression. Adenovirus-GM-CSF augmented the antitumor effect of carrier cells by increasing antiadenoviral and antitumoral CTL responses. This novel carrier cell-mediated viral transfection system might prove useful in a variety of types of cancer therapy.